-
1.发明授权公开(公告)号：US11154553B1
公开(公告)日：2021-10-26
申请号：US17304610
申请日：2021-06-23
发明人： Arash Raoufinia
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
-
2.发明授权公开(公告)号：US10980803B2
公开(公告)日：2021-04-20
申请号：US16710495
申请日：2019-12-11
发明人： Arash Raoufinia
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
-
3.发明申请公开(公告)号：US20220054482A1
公开(公告)日：2022-02-24
申请号：US17459221
申请日：2021-09-09
发明人： Arash Raoufinia
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
-
4.发明申请METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION 审中-公开向具有有害CYP2D6或CYP3A4酶功能的患者提供阿维哌唑的方法公开(公告)号：US20150087654A1
公开(公告)日：2015-03-26
申请号：US14034727
申请日：2013-09-24
发明人： Arash Raoufinia
IPC分类号： A61K31/496 , A61K45/06
CPC分类号： A61K31/496 , A61K9/0019 , A61K9/10 , A61K9/19 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
摘要翻译： 所公开的实施方案涉及在患有CYP2D6不良代谢者或CYP3A4不良代谢者或两者的患者中开始阿立哌唑治疗的方法。
-
5.发明申请公开(公告)号：US20230071995A1
公开(公告)日：2023-03-09
申请号：US17731494
申请日：2022-04-28
发明人： Arash Raoufinia
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
-
6.发明申请公开(公告)号：US20220071992A1
公开(公告)日：2022-03-10
申请号：US17206241
申请日：2021-03-19
发明人： Arash Raoufinia
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
-
7.发明申请公开(公告)号：US20210308127A1
公开(公告)日：2021-10-07
申请号：US17304606
申请日：2021-06-23
发明人： Arash Raoufinia
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
-
8.发明授权公开(公告)号：US11344547B2
公开(公告)日：2022-05-31
申请号：US17459221
申请日：2021-09-09
发明人： Arash Raoufinia
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
-
9.发明授权公开(公告)号：US11273157B2
公开(公告)日：2022-03-15
申请号：US17304606
申请日：2021-06-23
发明人： Arash Raoufinia
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
-
10.发明申请公开(公告)号：US20210315888A1
公开(公告)日：2021-10-14
申请号：US17304610
申请日：2021-06-23
发明人： Arash Raoufinia
摘要： The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.016 秒)
